SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934
(Amendment No.   )*

 

PLURISTEM THERAPEUTICS INC.

(Name of Issuer)

 

Common Stock, par value $0.00001 per share

(Title of Class of Securities)

 

72940R300

(CUSIP Number)

 

January 24, 2022

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

  ☐  Rule 13d-1(b)
     
  ☒ Rule 13d-1(c)
     
  ☐  Rule 13d-1(d)

 

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

CUSIP No. 72940R300 13G Page 2 of 9 Pages

 

1.

Names of Reporting Persons

Regals Capital Management LP

 

2.

Check the Appropriate Box if a Member of a Group

(See Instructions)

 

(a) ☐

(b) ☐

3.

SEC Use Only

 

4.

Citizenship or Place of Organization

Delaware

 

 

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

5.

 

Sole Voting Power

 

0

 

6.

Shared Voting Power

 

1,071,938

 

7.

Sole Dispositive Power

 

0

 

8.

Shared Dispositive Power

 

1,071,938

 

9.

Aggregate Amount Beneficially Owned by Each Reporting Person

 

1,071,938

 

10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares

(See Instructions)

 

 

☐

 

11.

Percent of Class Represented by Amount in Row (9)

 

3.34%

 

 

12.

Type of Reporting Person (See Instructions)

 

PN

 

 

 

CUSIP No. 72940R300 13G Page 3 of 9 Pages

 

1.

Names of Reporting Persons

Regals Fund LP

 

2.

Check the Appropriate Box if a Member of a Group

(See Instructions)

 

(a) ☐

(b) ☐

3.

SEC Use Only

 

4.

Citizenship or Place of Organization

Delaware

 

 

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

5.

 

Sole Voting Power

 

0

 

6.

Shared Voting Power

 

1,071,938

 

7.

Sole Dispositive Power

 

0

 

8.

Shared Dispositive Power

 

1,071,938

 

9.

Aggregate Amount Beneficially Owned by Each Reporting Person

 

1,071,938

 

10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares

(See Instructions)

 

 

☐

 

11.

Percent of Class Represented by Amount in Row (9)

 

3.34%

 

 

12.

Type of Reporting Person (See Instructions)

 

PN

 

 

 

CUSIP No. 72940R300 13G Page 4 of 9 Pages

 

1.

Names of Reporting Persons

David M. Slager

 

2.

Check the Appropriate Box if a Member of a Group

(See Instructions)

 

(a) ☐

(b) ☐

3.

SEC Use Only

 

4.

Citizenship or Place of Organization

Dutch

 

 

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

5.

 

Sole Voting Power

 

613,100

 

6.

Shared Voting Power

 

1,071,938

 

7.

Sole Dispositive Power

 

613,100

 

8.

Shared Dispositive Power

 

1,071,938

 

9.

Aggregate Amount Beneficially Owned by Each Reporting Person

 

1,685,038

 

10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares

(See Instructions)

 

 

☐

 

11.

Percent of Class Represented by Amount in Row (9)

 

5.25%

 

 

12.

Type of Reporting Person (See Instructions)

 

IN

 

 

 

CUSIP No. 72940R300 13G Page 5 of 9 Pages

 

Item 1(a). Name of Issuer

 

Pluristem Therapeutics Inc.

 

Item 1(b). Address of Issuer’s Principal Executive Offices

 

MATAM Advanced Technology Park, Building No. 5 Haifa, Israel 3508409.

 

Item 2(a). Name of Person Filing

 

This Schedule is filed on behalf of each of the following Reporting Persons:

 

(1) Regals Capital Management LP (“Regals Management”)

 

(2) Regals Fund LP (“Regals Fund”)

 

(3) David M. Slager (“Mr. Slager”)

 

Item 2(b). Address of Principal Business Offices or, if None, Residence

 

The address of each Reporting Person is:

 

c/o Regals Capital Management LP
152 West 57th Street, 9th Floor
New York, NY 10019

 

Item 2(c). Citizenship

 

Each of Regals Management and Regals Fund is a Delaware limited partnership.

 

Slager is a citizen of The Netherlands.

 

Item 2(d). Title of Class of Securities

 

Common Stock.

 

Item 2(e). CUSIP Number

 

72940R300

 

Item 3. If the statement is being filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the filing person is a:

 

Not Applicable

 

(a) ☐  Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
(b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
(c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
(d) ☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
(e) ☐ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

 

 

CUSIP No. 72940R300 13G Page 6 of 9 Pages

 

(f) ☐ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
     
(g) ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
     
(h) ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
(i) ☐ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
     
(j) ☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
     
(k) ☐ Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

 

If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: __________________________________________________________________________

 

Item 4. Ownership

 

(a) Amount beneficially owned:

 

As of the date hereof, Regals Fund directly owned 1,071,938 shares of Common Stock. Regals Management, as the investment manager of Regals Fund, may be deemed to beneficially own the shares of Common Stock owned directly by Regals Fund. Mr. Slager, as the managing member of the general partner of Regals Management, may be deemed to beneficially own the shares of Common Stock beneficially owned by Regals Management, in addition to the 613,100 shares of Common Stock he owns directly

 

(b) Percent of class:

 

The aggregate percentage of shares of Common Stock reported owned by each person named herein is based upon 32,099,615 shares of Common Stock outstanding as of September 30, 2021, which is the total number of shares of Common Stock outstanding as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 8, 2021. As of the date hereof, each of Regals Fund and Regals Management may be deemed to have beneficially owned approximately 3.34% of the shares of Common Stock outstanding and Mr. Slager may be deemed to beneficially have owned approximately 5.25% of the shares of Common Stock outstanding.

 

(c) Number of shares as to which the person has:

 

(i) Sole power to vote or to direct the vote:

 

See Cover Pages Items 5-9

 

(ii) Shared power to vote or to direct the vote:

 

See Cover Pages Items 5-9

 

(iii) Sole power to dispose or to direct the disposition of:

 

See Cover Pages Items 5-9

 

(iv) Shared power to dispose or to direct the disposition of:

 

See Cover Pages Items 5-9

 

 

CUSIP No. 72940R300 13G Page 7 of 9 Pages

 

Item 5. Ownership of Five Percent or Less of a Class

 

Not Applicable

 

Item 6. Ownership of More Than Five Percent on Behalf of Another Person

 

Not Applicable

 

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

 

Not Applicable

 

Item 8. Identification and Classification of Members of the Group

 

Not Applicable

 

Item 9. Notice of Dissolution of Group

 

Not Applicable

 

Item 10. Certification

 

By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

 

 

CUSIP No. 72940R300 13G Page 8 of 9 Pages

 

SIGNATURE

 

After reasonable inquiry and to the best of its knowledge and belief, each Reporting Person certifies that the information set forth in this statement is true, complete and correct.

 

Dated: January 26, 2022 Regals Capital Management LP
  By: Regals Capital Holdings LLC, its general partner
   
  /s/ David M. Slager
  Name: David M. Slager
  Title: Managing Member
   
Dated: January 26, 2022 Regals Fund LP
  By: Regals Fund GP LLC, its general partner
   
  /s/ David M. Slager
  Name: David M. Slager
  Title: Managing Member
   
Dated: January 26, 2022 David M. Slager
   
  /s/ David M. Slager
  Name: David M. Slager

 

Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

 

 

CUSIP No. 72940R300 13G Page 9 of 9 Pages

 

EXHIBIT INDEX

 

Exhibit   Description
     
99.1   Agreement of Joint Filing. (Filed herewith)

 

 

 

 

Pluristem Therapeutics (NASDAQ:PSTI)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Pluristem Therapeutics Charts.
Pluristem Therapeutics (NASDAQ:PSTI)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Pluristem Therapeutics Charts.